Akeso Begins Phase II Trial of Bispecific ADC in Breast Cancer
Hong Kong, China, August 9, 2026 Akeso, Inc. has announced the first patient dosing in a Phase II clinical...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Hong Kong, China, August 9, 2026 Akeso, Inc. has announced the first patient dosing in a Phase II clinical...
Chicago, Illinois, USA, August 10, 2026 Beltone has announced Beltone Illuminateâ„¢, a new family of premium hearing aids designed...
